Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.
Nonalcoholic Steatohepatitis (NASH)
Viking
VK2809 A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF VK2809 ADMINISTERED FOR 52 WEEKS FOLLOWED BY A 4-WEEK OFF-DRUG PHASE IN SUBJECTS WITH BIOPSY PROVEN NON-ALCOHOLIC STEATOHEPATITIS WITH FIBROSIS(Stage 1-3)
Gilead
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
Galactin
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
AURORA (Allergan)
This is a Phase 3 study for the treatment of Stage 2 to 3 liver fibrosis in adult subjects with NASH. Must have a liver biopsy or have a historical one performed 6 months prior to screening.
Ulcerative Colitis
Eli Lilly (AMAN)
Phase 3 Study for Patients with Moderately to Severely Active Ulcerative Colitis. Must have failed 1 biologic.
GSK
A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Chron’s
Eli Lilly (AMAM)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-and Active Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease
Celltrion
A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 as Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease
Arena(cultivate)
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease
Gastroparesis
Takeda
Phase 2b Dose Response, Efficacy and Safety Study in Adult Subjects with Symptomatic Idiopathic or Diabetic Gastroparesis
Screening Colonoscopy
Guardant
The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer. No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.
